

# Gemini Stock Analysis Report

---

As a seasoned positional equity trader, I have analyzed the comprehensive data provided for AUROPHARMA.NS. My objective is to determine the viability of an intermediate-term entry (1-4 months) with a target of 5%-15% upside.

## Step 1: Audit the Data

- **Data Present:** Daily price charts (3-year), Long-term (4-year) and Short-term (6-quarter) fundamental metrics, Relative Strength (RS) analysis vs. ^CNXPHARMA, EMA Crossovers (20/50/200), Bollinger Bands, Supertrend, MACD, Volatility Squeeze analysis, and RSI-Volume Divergence.
  - **Data Missing:** Weekly/Monthly charts (necessary for confirmed long-term trend alignment) and Sector-wide peer comparison beyond the benchmark index.
  - **Confidence Level: High.** The report provides a deep confluence of technical indicators and fundamental trends, allowing for a highly objective assessment.
- 

## Step 2: Analyze the Setup

**Trend and Structure:** The stock is in a "Strong Uptrend" technically, characterized by a recent Golden Cross (2025-11-27) and price trading above the EMA 20, 50, and 200. However, the price has been consolidating in a tight range since November 2025 after a massive correction from its mid-2024 peak.

**Momentum and Volatility:** \* **The Squeeze:** This is the primary feature of the current chart. A "Volatility Squeeze" (Bollinger Band and ATR contraction) is currently active (Page 14-15). This suggests a significant move is imminent, but the direction is not yet confirmed. \* **Weakening Strength:** MACD momentum is "Weakening" (Page 12), and the RS Score of 51.1 (Page 4) indicates the stock is currently a "Weakening Leader." It is essentially drifting sideways. \* **Fundamentals:** Short-term fundamentals are a concern. Recent QoQ Revenue (-7.03%) and Net Income (-8.71%) are declining, which may act as a drag on any potential breakout.

**Confluence:** We have a technical uptrend fighting against weakening fundamental momentum and neutral relative strength. The "Squeeze" indicates a coil is ready to spring, but entering before the breakout is speculative rather than evidence-based.

---

## Step 3: Formulate the Recommendation

**Entry Advised: NO**

**Rationale:** While the trend is technically "up," the stock lacks the immediate momentum and fundamental tailwinds required for a high-probability positional trade. The "Weakening Leader" status and the declining QoQ earnings suggest the stock could easily break *down* from the current volatility squeeze or continue to underperform the broader pharma sector.

**Conditional Plan (The "Breakout" Setup):** If the stock clears its recent consolidation resistance, it would signal that the Volatility Squeeze has resolved to the upside, likely targeting the next major resistance levels.

# Gemini Stock Analysis Report

---

- **Condition to Buy:** Daily close above **INR 1245** (This clears the upper Bollinger Band and the recent December swing highs).
- **Entry Price:** INR 1248.00 (Trigger on confirmation of breakout).
- **Stop Loss:** INR 1155.00 (Just below the EMA 200 and current Supertrend support, representing ~7.5% risk).
- **Take Profit:** INR 1375.00 (Approx. 10% upside, targeting the resistance area established in late 2024).

**Risk Note:** Maintain strict position sizing. The pharma sector can be volatile, and given the contraction in recent earnings, any failure to hold the EMA 50 (INR 1179) should be viewed as a signal to exit immediately.

## News & Analyst Targets

As a stock research analyst, I have compiled the following report on **Aurobindo Pharma (AUROPHARMA)** based on market developments for the week of **December 22 - 28, 2025**.

### 1. Latest News for AUROPHARMA (This Week)

- **China JV Stake Expansion (Dec 23, 2025):** Aurobindo's subsidiary, *Helix Healthcare B.V.*, entered into a binding agreement to acquire an additional **20% stake** in its Chinese joint venture, *Luoxin Aurovitas Pharma*, for **\$5.125 million**. This increases its holding to 50%. The company also secured the right to acquire the remaining 50% by December 2029 for ~\$18.86 million. This move is aimed at scaling up the manufacturing of inhalation products.
- **Termination of Biosimilar Pact (Dec 27, 2025):** Subsidiary *CuraTeQ Biologics* mutually terminated its licensing agreement with US-based *BioFactura* for the development of **BFI-751** (a biosimilar to Stelara/Ustekinumab). The company cited "strategic portfolio prioritization" and clarified that this would not materially impact its broader biosimilars strategy.
- **Trading Window Closure:** The company announced that its trading window for insiders will be closed from **January 1, 2026**, until 48 hours after the declaration of Q3 financial results.

### 2. Brokerage Upgrades/Downgrades

- **Elara Capital (Dec 24, 2025):** Reiterated its "**Buy**" rating. The brokerage remains upbeat on Aurobindo's valuation and growth triggers in the inhalation and biosimilars space, despite the recent termination of the BioFactura pact.
- **MarketsMojo (Dec 28, 2025):** Adjusted its technical evaluation from "**Bearish**" to "**Mildly Bearish**." While the technical outlook is cautious due to recent underperformance, the firm highlighted the stock's attractive valuation and low debt-to-equity ratio.
- **CLSA (Late 2025):** Maintains an "**Outperform**" rating (upgraded earlier from Hold). They recently tempered their target slightly to reflect conservative earnings forecasts for FY27 but remain positive on the Pen-G plant commercialization.

### 3. Other News Impacting AUROPHARMA

- **Regulatory Inspections (Direct Impact):** In the week prior (mid-December), the USFDA issued **Form 483 with 5 observations** for Unit-IV (APL Healthcare) in Andhra Pradesh. Earlier in the month, Unit-V (Apitoria Pharma) also received 3 observations. The company has classified these as "procedural" and is in the process of responding.
- **China Turnaround Strategy:** Management recently indicated that the China facility, currently incurring a loss of ~\$1M per quarter, is expected to **break even by Q4 FY26**. The increased stake in the JV is a direct step toward this goal.
- **Sector Headwinds (Indirect Impact):** The broader Indian pharma sector is facing volatility due to technical sentiment and concerns over potential US trade policy shifts (tariffs) under the new administration.

# Gemini Stock Analysis Report

---

## 4. Latest Analyst Targets & Ratings

The following table summarizes the most recent projections from the analyst community:

Brokerage/Firm	Rating	Target Price (INR )	Date Reported	Potential Upside
Elara Capital	Buy	1,568	Dec 24, 2025	~28%
Motilal Oswal	Buy	1,430	Dec 04, 2025	~18%
Axis Capital	Buy	1,260	Nov 06, 2025	~4%
HSBC	Buy	1,300	Oct 13, 2025	~7%
CLSA	Outperform	1,400	Nov 06, 2025	~15%
Kotak Securities	Sell	1,115	Nov 06, 2025	-8% (Downside)
Consensus Average	Buy	1,298	Dec 2025	~8%

**Analyst Summary:** The outlook remains largely positive among domestic brokerages (Elara, Motilal Oswal), who see the current price as a buying opportunity following a year of underperformance. However, global firms like Kotak remain cautious due to regulatory overhangs and US pricing pressures.

# Stock Detailed Analysis Report

## AUROPHARMA.NS

Current Price: ₹1206.20

Generated: 2025-12-28 10:31

# AUROPHARMA.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	9.31%	10.33%
Net Income	Yes	Yes	9.86%	9.59%
ROE	No	Yes	0.41%	-0.31%
EPS	Yes	Yes	10.43%	9.79%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	-7.03%	1.23%
Net Income	No	-8.71%	-2.37%
ROE	Yes	4.52%	4.52%
EPS	No	4.00%	-3.39%

# AUROPHARMA.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Weakening Leader</b>
RS Score:	51.1/100
:	

## == RS RATIOS ==:

1M RS:	<b>0.990 [Neutral]</b>
3M RS:	<b>1.075 [Leader]</b>
6M RS:	<b>1.032 [Leader]</b>
1Y RS:	<b>0.963 [Neutral]</b>
:	




## == TURNAROUND ANALYSIS ==:

Turnaround Status:	<b>Not Detected</b>
:	

## SIGNAL CRITERIA::

✗ Emerging RS:	<b>Not accelerating</b>
✓ Medium-term Lagging:	1Y=0.963 ( $\leq 1.0$ )
✓ Performance Improving:	3M (+10.0%) > 6M (+7.4%)


**Relative Strength Analysis: AUOPHARMA.NS vs ^CNXPHARMA**  
**Classification: Weakening Leader**  
**Price Performance Comparison (Normalized)**



## AUROPHARMA.NS - EMA Crossover Summary

<b>EMA 20:</b>	1201.94
<b>EMA 50:</b>	1179.62
<b>EMA 200:</b>	1159.87
<b>Trend Status:</b>	<b>Strong Uptrend</b>
<b>Golden Cross Date:</b>	2025-11-27 00:00:00
<b>Golden Cross Price:</b>	1235.80


# AUROPHARMA.NS EMA Crossover Analysis



## AUOPHARMA.NS - Bollinger Bands Summary

<b>Current Price:</b>	1206.20
<b>Upper Band:</b>	1242.95
<b>Middle Band (SMA 20):</b>	1202.02
<b>Lower Band:</b>	1161.10
<b>%B:</b>	0.5510
<b>Band Width:</b>	0.0681
<b>Status:</b>	Upper Half
<b>Signal:</b>	None

## AUOPHARMA.NS Bollinger Bands (20, 2) Analysis




## AUROPHARMA.NS - Supertrend Summary

**Status:** UPTREND (Buy)

**Supertrend Value:** 1158.19

**Signal Identified On:** 2025-09-11

### Supertrend Analysis for AUROPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## AUROPHARMA.NS - MACD Summary

<b>MACD Line:</b>	7.81
<b>Signal Line:</b>	7.72
<b>Histogram:</b>	0.09
<b>Trend:</b>	<b>Bullish</b>
<b>Momentum:</b>	<b>Weakening</b>
<b>Signal:</b>	None

### AUROPHARMA.NS Price






### AUROPHARMA.NS MACD (12, 26, 9)



## AUOPHARMA.NS - Volatility Squeeze Summary

<b>BB Width:</b>	0.0681
<b>ATR:</b>	24.4500
<b>Total Signals:</b>	41
<b>Signal 1:</b>	BB Squeeze + ATR Contraction at 2025-12-18 00:00:00 (Price: 1206.20)
<b>Signal 2:</b>	BB Squeeze + ATR Contraction at 2025-12-19 00:00:00 (Price: 1211.40)
<b>Signal 3:</b>	BB Squeeze + ATR Contraction at 2025-12-22 00:00:00 (Price: 1211.40)
<b>Signal 4:</b>	BB Squeeze at 2025-12-24 00:00:00 (Price: 1211.40)
<b>Signal 5:</b>	BB Squeeze at 2025-12-26 00:00:00 (Price: 1206.20)

# AUROPHARMA.NS - Volatility Squeeze Analysis



## AUROPHARMA.NS - RSI-Volume Summary

<b>Current RSI:</b>	53.16
<b>Current Volume:</b>	310348
<b>Volume MA 20:</b>	634375
<b>Bullish Divergences:</b>	1
<b>Bearish Divergences:</b>	3
<b>Bullish Div 1:</b>	Date: 2025-02-03 00:00:00, Price: 1125.40
<b>Bearish Div 1:</b>	Date: 2024-08-30 00:00:00, Price: 1569.40
<b>Bearish Div 2:</b>	Date: 2025-10-13 00:00:00, Price: 1136.80

# AUROPHARMA.NS RSI-Volume Divergence Analysis

